Emerging Treatments in Multiple Myeloma

Video Library —June 2, 2020
Kathryn Maples, PharmD, BCOP
Charise Gleason, MSN, NP-BC, AOCNP

Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, talk about the emerging treatments for MM, including monoclonal antibodies, 2nd-generation protease inhibitors, and targeted therapies. These changes pose challenges to healthcare providers struggling to keep up with these changes, but this is good news for patients with expanding treatment options.

Related Articles
Landscape Shifts in Treating Multiple Myeloma
Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, Chelsea Sprouse, RN-BSN, MSN, NP-C
|
Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, enumerate the major landscape shifts over the past 5 years in treating MM, including an increasing number of treatment options, the emergence of MRD testing to guide therapy, the availability of clinical trials, and the deeper, more durable responses new agents provide.
Benefits and Challenges with Emerging Agents for Multiple Myeloma
Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, Chelsea Sprouse, RN-BSN, MSN, NP-C
|
Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, discuss the convenience of oral therapy along with challenges in adherence to oral therapy. Additionally, they’ll discuss the tolerability of emerging drugs, the emergence of novel adverse events with new agents, and best practices in providing supportive care for patients on these novel agents.
Current Standard of Care for Patients with Multiple Myeloma Based on Their Eligibility for Autologous Stem-Cell Transplant
Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, Chelsea Sprouse, RN-BSN, MSN, NP-C
|
Video Library
Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, RN-BSN, MSN, NP-C, discuss the current standard of care for both high- and low-risk patients with newly diagnosed or recurrent/refractory multiple myeloma who are initially not eligible for autologous stem-cell transplant and who subsequently become transplant-eligible.
Last modified: June 2, 2020

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code